Shares of Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) have been assigned an average rating of “Hold” from the eighteen research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.53.
Several brokerages recently weighed in on TDOC. Citigroup cut their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. TD Cowen boosted their target price on shares of Teladoc Health from $6.00 to $8.00 and gave the company a “hold” rating in a research note on Monday, November 9th. Stifel Nicolaus upped their target price on shares of Teladoc Health from $5.50 to $6.50 and gave the stock a “hold” rating in a research report on Thursday, October 29th. Bank of America raised their price target on shares of Teladoc Health from $10.50 to $11.50 in a research note on Thursday, October 29th. Finally, Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th.
Check Out Our Latest Research Report on TDOC
Teladoc Health Stock Performance
Teladoc Health (NYSE:TDOC – Get Free Report) last released its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative return on equity of 11.63% and a negative net margin of 6.27%. The business had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The business’s revenue for the quarter was down 3.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Teladoc Health will post -0.86 earnings per share for the current year.
Insider Buying and Selling
In other Teladoc Health news, CEO Charles III sold 17,805 shares of Teladoc Health stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the sale, the chief executive officer owned 465,535 shares of the company’s stock, valued at $2,839,763.50. The trade was a 3.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 29,432 shares of the business’s stock in a transaction on Friday, November 6th. The stock was sold at an average price of $9.20, for a total value of $270,774.40. Following the transaction, the insider owned 35,312 shares of the company’s stock, valued at $324,870.40. This trade represents a 45.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 47,892 shares of company stock valued at $383,086 over the last three months. Corporate insiders own 0.70% of the company’s stock.
Institutional Investors Weigh In On Teladoc Health
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in shares of Teladoc Health by 1.3% in the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after acquiring an additional 107,400 shares during the period. Monaco Asset Management SAM acquired a new position in shares of Teladoc Health during the second quarter valued at approximately $26,864,000. Pale Fire Capital SE increased its stake in shares of Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after acquiring an additional 1,454,288 shares during the period. Quantinno Capital Management LP raised its holdings in Teladoc Health by 128.0% during the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after purchasing an additional 1,471,631 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC raised its holdings in Teladoc Health by 1,017.4% during the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider’s stock worth $9,571,000 after purchasing an additional 1,502,488 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.
Teladoc Health Company Profile
Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.
Featured Stories
- Five stocks we like better than Teladoc Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
